抗血小板藥物市場：依藥物類別、給藥途徑、應用及地區分類。

Antiplatelet Drugs Market, By Drug Class, By Mode of Administration, By Application, By Geography

出版日期: 2026年02月12日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2026年，抗血小板藥物市場規模將達到29.07億美元，到2033年將達到49.2億美元。預計從2026年到2033年，該市場將以7.83%的複合年成長率成長。

分析範圍		分析詳情
基準年	2025	市場規模（2026 年）	29.07億美元
效能數據	2020-2024	預測期	2026-2033
預測期（2026-2032 年）複合年成長率	7.83%	預計金額（2033 年）	49.2億美元

抗血小板藥物用於治療有心肌梗塞病史的患者，有助於預防心肌梗塞復發。抗血小板藥物包括阿斯匹靈、Clopidogrel、普拉格雷和替格瑞洛。除非出現過敏反應，否則建議所有急性冠狀動脈症候群（ACS）患者服用阿斯匹靈。阿斯匹靈通常與口服抗血小板藥物合併使用，例如Clopidogrel、普拉格雷或替格瑞洛。普拉格雷用於治療ACS患者或接受經皮冠狀動脈介入治療（PCI）的患者。Clopidogrel和替格瑞洛有助於預防成人急性冠狀動脈症候群（ACS）患者以及接受冠狀動脈繞道手術移植術（CABG）或PCI的患者的動脈粥樣硬化血栓事件。

市場動態

肥胖、糖尿病和心血管疾病等慢性病發病率的上升增加了心臟病發作的風險，從而推動了對血小板藥物的需求。例如，根據美國糖尿病協會的數據，2019年美國有3,730萬名公民患有糖尿病，佔總人口的11.3%。在這3730萬成年人中，約有190萬人患有第1型糖尿病，其中包括約24.4萬名兒童和青少年。在3,730萬名糖尿病患者中，2,870萬人已確診，而850萬人仍未確診。 2019年，美國有9,600萬18歲以上的公民處於糖尿病前期。每年約有140萬美國公民被診斷出患有糖尿病。根據美國疾病管制與預防中心（CDC）的數據，2017年至2018年間，美國每年因心臟病造成的經濟損失約2,290億美元。這包括醫療服務和藥物費用，以及因死亡造成的生產力損失。根據美國疾病管制與預防中心統計，2019年，約有2010萬20歲及以上的成年人患有冠狀動脈疾病。

本報告的主要特點

本報告指出了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
本節根據以下參數介紹全球抗血小板藥物市場主要企業的概況：公司概況、產品系列、主要亮點、財務績效和策略。
本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
《全球抗血小板藥物市場》報告面向該行業的眾多相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過分析全球抗血小板藥物市場中使用的各種策略矩陣來促進決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 亞太其他地區
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

熱圖分析
公司簡介
- AstraZeneca Plc
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Daiichi Sankyo, Inc.
- Eli Lilly and Company
- Merck &Co., Inc.
- Otsuka Pharmaceutical Company, Ltd.
- Sanofi
- The Medicines Company

第9章

參考
分析方法

簡介目錄

Product Code: CMI2190

Antiplatelet Drugs Market is estimated to be valued at USD 2,907 Mn in 2026 and is expected to reach USD 4,920 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.83% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 2,907 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	7.83%	2033 Value Projection:	USD 4,920 Mn

Antiplatelet drugs are prescribed to individuals with a history of heart attacks and these drugs aid in reducing reoccurrence of heart attacks. Some of the antiplatelet medications include, aspirin, clopidogrel, prasugrel, and ticagrelor. Aspirin is recommended for all patients with Acute Coronary Syndrome (ACS), in the absence of hypersensitivity. It is prescribed along with one of the oral antiplatelet agents including Clopidogrel, Prasugrel, and Ticagrelor. Prasugrel is prescribed for patients suffering from ACS and for those undergoing Percutaneous Coronary Intervention (PCI). Clopidogrel and Ticagrelor aid in preventing atherothrombotic events in adult patients with ACS, and those who are treated with Coronary Artery Bypass Grafting (CABG) or PCI.

Market Dynamics

Increasing incidence of chronic diseases such as obesity, diabetes, and cardiovascular diseases (CVDs) is increasing the risk of heart attacks, which in turn is propelling demand for antiplatelet drugs. For instance, according to American Diabetes Association, in 2019, 37.3 million U.S. citizens or 11.3% of the population, had diabetes. Of the 37.3 million adults, nearly 1.9 million U.S. citizens had type 1 diabetes, including about 244,000 children and adolescents. Of the 37.3 million adults with diabetes, 28.7 million were diagnosed, and 8.5 million were undiagnosed. In 2019, 96 million U.S. citizens age 18 and older had prediabetes. 1.4 million U.S. citizens are diagnosed with diabetes every year. According to report by Centers for Disease Control and Prevention, heart disease cost the U.S. about US$229 billion each year from 2017 to 2018. This included the cost of health care services, medicines, and lost productivity due to death. In the U.S. according to the Center for disease control, about 20.1 million adults age 20 and older had Coronary Artery Disease in the year 2019.

Key features of the study

This report provides an in-depth analysis of the global antiplatelet drugs market , and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global antiplatelet drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Sanofi, and The Medicines Company
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global antiplatelet drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antiplatelet drugs market

Market Segmentation

Drug Class Insights (Revenue, USD Mn, 2026 - 2033)
- Irreversible Cyclooxygenase (COX) Inhibitors
- Adenosine Diphosphate (ADP) Receptor Inhibitors
- Glycoprotein IIB/IIIA Inhibitors
- Adenosine Reuptake Inhibitors
- Thromboxane Inhibitors and Phosphodiesterase Inhibitors
Mode of Administration Insights (Revenue, USD Mn, 2026 - 2033)
- Oral
- Intravenous
Application Insights (Revenue, USD Mn, 2026 - 2033)
- Angioplasty
- Arterial Thrombosis
- Myocardial Infarction
- Percutaneous Coronary Interventions
- Others
Regional Insights (Revenue, USD Mn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- AstraZeneca Plc
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Daiichi Sankyo, Inc.
- Eli Lilly and Company
- Merck & Co., Inc.
- Otsuka Pharmaceutical Company, Ltd.
- Sanofi
- The Medicines Company

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Mode of Administration
- Market Snapshot, By Application
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Recent Developments
Acquisitions and Partnerships Scenario
Technology Overview
Regulatory Scenario
Pricing Analysis
Epidemiology Analysis
PORTER'S Five Forces

4. Global Antiplatelet Drugs Market, By Drug Class, 2026 - 2033, (USD Mn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Irreversible Cyclooxygenase (COX) Inhibitors
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Adenosine Diphosphate (ADP) Receptor Inhibitors
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Glycoprotein IIB/IIIA Inhibitors
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Adenosine Reuptake Inhibitors
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Thromboxane Inhibitors and Phosphodiesterase Inhibitors
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

5. Global Antiplatelet Drugs Market, By Mode of Administration, 2026 - 2033, (USD Mn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Oral
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Intravenous
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

6. Global Antiplatelet Drugs Market, By Application, 2026 - 2033, (USD Mn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Angioplasty
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Arterial Thrombosis
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Myocardial Infarction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Percutaneous Coronary Interventions
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Others
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

7. Global Antiplatelet Drugs Market, By Region, 2026 - 2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Mode of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
  - U.S.
  - Canada
Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Mode of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Mode of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Mode of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Mode of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Mode of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Company Profiles
- AstraZeneca Plc
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Boehringer Ingelheim GmbH
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Bristol-Myers Squibb Company
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Daiichi Sankyo, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Eli Lilly and Company
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Merck & Co., Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Otsuka Pharmaceutical Company, Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Sanofi
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- The Medicines Company
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies